--- title: "MIRA Pharmaceuticals (MIRA) news: Nasdaq notice" url: "https://aibio.space/companies/mira-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MIRA Nasdaq notice news: Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027. MIRA Pharmaceuticals, Inc." --- MIRA MIRA Pharmaceuticals, Inc. NASDAQ · United States # MIRA Pharmaceuticals (MIRA) news MIRA Nasdaq notice news Listings · 2026-07-31 ## [Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/) Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million. ## Latest MIRA Pharmaceuticals news 1. 2025-09-30 Mergers [MIRA Pharmaceuticals closes SKNY acquisition in all-stock deal](https://aibio.space/news/mira-pharmaceuticals-closes-skny-acquisition-all-stock-deal/) SKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal. 2. 2025-04-11 Listings [MIRA Pharmaceuticals gets Nasdaq notice on $2.5 million stockholders' equity requirement](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-stockholders/) Nasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion. 3. 2025-04-11 Listings [MIRA Pharmaceuticals gets Nasdaq notice over $2.5 million equity rule](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-equity-rule/) MIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete. ## MIRA Pharmaceuticals at a glance - **Ticker**: MIRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $8.1 million ### Related companies - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) NASDAQ: RNAZ - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) NASDAQ: AVBP - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) NASDAQ: RVMD - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR - [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) NASDAQ: DFTX - [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI ### Also on NASDAQ - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) JSPR - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA - [Jazz Pharmaceuticals](https://aibio.space/companies/jazz-pharmaceuticals/) JAZZ - [Immunome](https://aibio.space/companies/immunome/) IMNM - [Bionano Genomics](https://aibio.space/companies/bionano-genomics/) BNGO - [AtriCure](https://aibio.space/companies/atricure/) ATRC ## MIRA Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | | Net income (loss) | [-$10.4 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | | Cash from operations | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | [-$5.6 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | | Cash and equivalents | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226037366/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/) | | Short-term investments | [$4.7 million](https://www.sec.gov/Archives/edgar/data/1904286/000149315226037366/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.6 million, plus short-term investments of $4.5 million, $8.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about MIRA Pharmaceuticals Has MIRA Pharmaceuticals received a Nasdaq deficiency notice? Our latest story on this, dated Jul 31, 2026: "Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/). What is the ticker symbol of MIRA Pharmaceuticals? MIRA Pharmaceuticals, Inc. trades under the ticker MIRA on NASDAQ. Where is MIRA Pharmaceuticals listed? MIRA Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:K6S; LSX:A3EQWL. What is the SEC CIK of MIRA Pharmaceuticals? The SEC Central Index Key (CIK) for MIRA Pharmaceuticals, Inc. is 1904286. Its filings are on SEC EDGAR. How many shares does MIRA Pharmaceuticals have outstanding? 42,022,087 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is MIRA Pharmaceuticals listed under? Our directory records MIRA Pharmaceuticals, Inc. under United States. What does MIRA Pharmaceuticals do? Our directory classifies MIRA Pharmaceuticals, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of MIRA Pharmaceuticals? The ISIN recorded for MIRA Pharmaceuticals, Inc. is US60458C1045. Does aibio.space cover MIRA Pharmaceuticals? aibio.space lists MIRA Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is MIRA Pharmaceuticals incorporated? SEC records list its state or country of incorporation as FL. Is MIRA Pharmaceuticals profitable? MIRA Pharmaceuticals, Inc. reported a net loss of $10.4 million for the fiscal year ended Dec 31, 2025, and used $4.7 million of cash in operations, per its annual report to the SEC. How much does MIRA Pharmaceuticals spend on research and development? $1.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does MIRA Pharmaceuticals have? $8.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest MIRA Pharmaceuticals (MIRA) stock news? Our latest story on MIRA Pharmaceuticals, dated Jul 31, 2026: "Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027". Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million. [Source](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/). How long will MIRA Pharmaceuticals's cash last? From our story of Jul 31, 2026: The auditor's report on the 2025 financial statements contains an explanatory paragraph on the company's ability to continue as a going concern, and the company says its losses and negative cash flows raise substantial doubt about that ability absent adequate new debt or equity financing. [Source](https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/). ## Investor discussion: MIRA Pharmaceuticals Members talk about MIRA Pharmaceuticals (MIRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at MIRA Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-07-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000149315226035665/form8-k.htm) 2. 2025-12-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1904286/000149315225026444/form424b5.htm) 3. 2025-09-30 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/form8-k.htm) 4. 2025-05-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/form8-k.htm) 5. 2025-05-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000164117225009155/form8-k.htm) 6. 2025-04-16 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1904286/000164117225005104/form424b5.htm) 7. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/form8-k.htm) 8. 2024-12-20 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1904286/000149315224051091/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MIRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-MIRA/). ## SEC filings and registration - **SEC name**: Mira Pharmaceuticals, Inc. - **CIK**: 1904286 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MIRA (Nasdaq) - **State or country of incorporation**: FL - **Filer category**:
Emerging growth company - **Business address**: 1200 BRICKELL AVENUE, MIAMI, FL, 33131 - **Phone**: 813-369-5150 - **Shares outstanding**: 42,022,087 as of 2026-08-10 (10-Q filed 2026-08-12) - **Former names**: Mira1a Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226048022/form8-k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226043051/form8-k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226042927/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/form8-k.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1904286/000149315226037366/form10-q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226036262/form8-k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1904286/000149315226035665/form8-k.htm) filed 2026-07-31 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1904286/000149315226035027/formdef14a.htm) filed 2026-07-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001904286), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details MIRA Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MIRA, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: MIRA Pharmaceuticals, Inc. - **Ticker**: MIRA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US60458C1045 - **Other listed symbols**: GETTEX:K6S; LSX:A3EQWL - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MIRA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/mira-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MIRA Pharmaceuticals (MIRA) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/mira-pharmaceuticals/